Cerebrolysin
From PeptidePlaza, the free peptide reference · Entry #050 · Nootropic · Hand-curated entry · Editorial standards
Cerebrolysin (also known as FPF-1070, Cerebrolysin, Cere) is a nootropic research peptide. A low-molecular-weight peptide fraction from porcine brain tissue, used across Europe and Asia for stroke and dementia for decades. Decades of trials, and the Cochrane verdict is still not favourable.
Cerebrolysin is a preparation of low-molecular-weight peptides and free amino acids produced by enzymatic breakdown of purified porcine brain proteins, with all components below approximately 10 kDa so they can cross the blood-brain barrier. It is not a single molecule but a defined-process biological, registered in more than 40 countries across Europe, Asia, Latin America and the CIS for ischaemic stroke, traumatic brain injury and dementia, though never approved in the US or by the EMA centrally. The proposed mechanism is neurotrophic mimicry: the peptide fraction is claimed to reproduce aspects of endogenous neurotrophic factor activity (CNTF, GDNF, IGF-1-like effects), reducing excitotoxicity, limiting apoptosis, and supporting neurogenesis and synaptic plasticity. The clinical literature is large but uneven. Cochrane systematic reviews have found no convincing evidence of benefit for acute ischaemic stroke and noted a possible increase in non-fatal serious adverse events, while assessments in vascular dementia have reported modest cognitive improvement on some scales. Much of the trial base originates from a limited number of centres and from the manufacturer, which — combined with the difficulty of characterising a tissue-derived mixture — is the recurring criticism.
1 Mechanism of action
Proposed pleiotropic neurotrophic activity from a mixture of biologically active peptides: reduction of glutamate excitotoxicity, inhibition of calpain-mediated proteolysis, suppression of apoptotic cascades, modulation of amyloid processing, and support of neurogenesis and synaptic plasticity. No single active constituent has been isolated, and the mechanism is inferred from preparation-level effects rather than defined molecular pharmacology.
Primary targets: Not characterised — multiple proposed neurotrophic pathways
2 Reported effects
Effects below are those reported in the published literature cited on this page. They are not claims of clinical benefit and not medical advice.
2.1 Reported benefits
- Registered clinically in over 40 countries for stroke, TBI and dementia
- Modest cognitive improvements reported in some vascular dementia assessments
- Peptide fraction under 10 kDa designed to cross the blood-brain barrier
- Neuroprotective effects — reduced excitotoxicity and apoptosis — in preclinical models
- Decades of clinical use with a broadly characterised tolerability profile
2.2 Side effects
- Injection site reactions and pain
- Vertigo, headache and agitation
- Sensation of heat, sweating, flushing during infusion
- Hypersensitivity and allergic reactions (porcine-derived material)
- Possible increase in non-fatal serious adverse events reported in stroke meta-analysis
- Seizure threshold reduction reported rarely
3 Chemical and physical properties
| Purity (typical) | Standardised preparation — not a single-compound purity specification |
|---|---|
| Half-life | Not definable for a mixture; administered as IV infusion or IM injection in daily courses |
| Storage | −20 °C, lyophilised powder, desiccated |
| Solubility | Sterile water / bacteriostatic water |
| Receptors / targets | Not characterised — multiple proposed neurotrophic pathways |
3.1 Amino acid sequence
Enzymatically derived peptide fraction (<10 kDa) from purified porcine brain protein; not a defined sequence
4 Research dosages
Registered clinical use: 10–50 mL daily by slow IV infusion for 10–20 day courses, repeated periodically; lower doses (5–10 mL) given IM.
5 Research studies (6)
- Cerebrolysin for Acute Ischaemic Stroke (Cochrane Systematic Review)
Cochrane Database of Systematic Reviews (2020) · Meta-Analysis · N=2,202 (7 trials)Systematic review and meta-analysis of randomised trials of cerebrolysin in acute ischaemic stroke.Key finding: No evidence of benefit on death or dependency; a possible increase in non-fatal serious adverse events was noted. - Cerebrolysin for acute ischaemic stroke.
The Cochrane database of systematic reviews (2023) · Systematic ReviewCerebrolysin is a mixture of low-molecular-weight peptides and amino acids derived from porcine brain, which has potential neuroprotective properties. - Cerebrolysin for stroke, neurodegeneration, and traumatic brain injury: review of the literature and outcomes.
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (2021) · ReviewCerebrolysin therapy has the potential to significantly aid in the treatment of a wide variety of debilitating neurological diseases including ischemic strokes, neurodegenerative disorders, and traumatic brain... - Cerebrolysin after moderate to severe traumatic brain injury: prospective meta-analysis of the CAPTAIN trial series.
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (2021) · Meta-AnalysisThis prospective meta-analysis summarizes results from the CAPTAIN trial series, evaluating the effects of Cerebrolysin for moderate-severe traumatic brain injury, as an add-on to usual care. - Cerebrolysin for vascular dementia.
The Cochrane database of systematic reviews (2019) · Meta-AnalysisAlthough vascular dementia is the second most common cause of dementia globally, evidence-based treatments are still lacking. - Cerebrolysin: a multi-target drug for recovery after stroke.
Expert review of neurotherapeutics (2018) · ReviewCerebrolysin is a neuropeptide preparation with neurotrophic effects and promotes recovery after brain injury.
6 Safety and risk profile
6.1 Regulatory status
Cerebrolysin is currently classified as Not approved. It has no approved human indication in the United States; availability elsewhere does not imply demonstrated safety or efficacy.
Safety score: 60/100 — moderate concern. Derived from clinical data volume, known risks and regulatory status.
6.2 Contraindications
Conditions and populations in which use is contraindicated:
- Epilepsy or history of seizures
- Severe renal impairment
- Known hypersensitivity to porcine proteins
- Pregnancy or lactation
- Status epilepticus
6.3 Drug interactions
| Drug or class | Interaction | Risk |
|---|---|---|
| MAO inhibitors | Manufacturer advises against concurrent use; theoretical additive effects on monoaminergic transmission. | High |
| Antidepressants | Reported potential for additive effects; caution advised in labelling. | Moderate |
| Amino acid infusions | Should not be mixed in the same infusion — incompatible preparation. | Moderate |
6.4 Long-term risks
- Repeated exposure to porcine-derived material raises sensitisation risk
- Long-term efficacy unproven despite decades of use
- Unknown consequences of repeated courses on neural plasticity
6.5 Research best practices
- Store at 2–8 °C (or per label, below 25 °C), protected from light
- Infuse slowly — rapid administration causes flushing, heat sensation and dizziness
- Never mix with amino acid solutions in the same infusion line
- Weigh the evidence honestly: registration in a country is not the same as demonstrated efficacy
7 Frequently asked questions
- Is cerebrolysin approved anywhere?
- It is registered in more than 40 countries including much of Eastern Europe, Russia, China and parts of Asia and Latin America, for stroke, TBI and dementia. It has never been approved by the FDA, and it holds no centralised EMA authorisation.
- What does the best evidence show?
- For acute ischaemic stroke, Cochrane analysis found no evidence of benefit for death or dependency and flagged a possible increase in non-fatal serious adverse events. Vascular dementia assessments have reported modest cognitive gains on some scales. The overall picture is decades of trials that have not produced convincing efficacy.
- Why is it hard to evaluate?
- It is a tissue-derived mixture rather than a defined molecule, so no single active constituent can be isolated, dose-response is hard to establish, and independent replication is difficult. A significant share of the trial base comes from a limited number of centres and from the manufacturer.
8 References
- Cerebrolysin for acute ischaemic stroke. PubMed (2023). Ziganshina LE, et al.. View source
- Cerebrolysin for stroke, neurodegeneration, and traumatic brain injury: review of the literature and outcomes. PubMed (2021). Fiani B, et al.. View source
- Cerebrolysin after moderate to severe traumatic brain injury: prospective meta-analysis of the CAPTAIN trial series. PubMed (2021). Vester JC, et al.. View source
- Cerebrolysin for vascular dementia. PubMed (2019). Cui S, et al.. View source
Related compounds
Entries that share a target, a mechanism, or a research area with Cerebrolysin.
Shares mechanism and characterised pharmacology
A Soviet-era thymic extract, not a single molecule. The centrepiece of the Khavinson bioregulator programme — and of a 6-to-12-year follow-up study whose mortality claims have never been replicated.
Shares proposed and pathways pharmacology
A synthetic tetrapeptide derived from the pineal gland peptide Epithalamin. Studied extensively by Vladimir Khavinson for telomerase activation, circadian regulation, and life extension in animal models.
Shares pathways and reduction pharmacology
A neuropeptide originally isolated from rabbit cerebrospinal fluid during slow-wave sleep. Studied for sleep regulation, stress buffering, pain modulation, and antioxidant effects across decades of European research.
Also nootropic
Substance P, also known as Neurokinin P, is an endogenous human peptide and a member of the tachykinin family.
Also nootropic
A cyclic heptapeptide melanocortin receptor agonist and active metabolite of Melanotan II. Unlike peripheral vasodilators, PT-141 acts centrally via the CNS to modulate arousal and food intake pathways.
Shares pathways and mechanism pharmacology
A potent six-amino acid growth hormone secretagogue. Among the strongest GHRPs studied, but notable for also elevating cortisol and prolactin — making it useful for studying GH axis effects with concurrent stress-hormone activation.